Therefore, we conducted the metagenomic and untargeted plasma/faecal metabolomic study in NSCLC patients receiving neoadjuvant anti‐PD‐1 immunochemotherapy. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.